# TTRX (Turn Therapeutics Inc.) - SEC EDGAR Financial Statements

> Turn Therapeutics Inc. reported $16.35M in total assets and a net loss of $12.77M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/TTRX
- Markdown: https://convexityos.com/fundamentals/TTRX.md
- SEC CIK: 0002023016
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:40 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002023016&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$7.05M | Operating profit |
| Net Income | FY 2025 | -$12.77M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.42 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $9.43M | Total debt: $6.23M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Research & Development | $266K | $246K |
| Total Operating Expenses | $5.86M | $1.80M |
| **Operating Income** | -$5.86M | -$1.80M |
| **EBITDA** | -$5.81M | -$1.75M |
| Interest Income | $30K | $29K |
| **Net Income** | -$3.19M | -$1.77M |
| Basic EPS | -$0.12 | -$0.07 |
| **Diluted EPS** | -$0.12 | -$0.07 |
| Basic Shares Outstanding | 27.7M | 26.6M |
| Diluted Shares Outstanding | 27.7M | 26.6M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $605K | $475K | $109K | $35K | $159K | $63K | $9.3K | $153K |
| Total Operating Expenses | $1.98M | $1.63M | $1.25M | $2.19M | $1.91M | $1.37M | $385K | $673K |
| **Operating Income** | -$1.98M | -$1.63M | -$1.25M | -$2.19M | -$1.91M | -$1.37M | -$385K | -$673K |
| Interest Income | $84K | -- | $50K | $14K | $5.1K | -- | $5.2K | $6.5K |
| Interest Expense | $341K | -- | -- | -- | -- | -- | -- | -- |
| **Net Income** | -$6.23M | -$5.85M | -$971K | $279K | -$1.90M | -$1.24M | -$329K | -$666K |
| Basic EPS | -$0.21 | -$0.20 | -$0.03 | -- | -$0.07 | -$0.05 | -$0.01 | -$0.03 |
| **Diluted EPS** | -$0.21 | -$0.20 | -$0.03 | -- | -$0.07 | -$0.05 | -$0.01 | -$0.03 |
| Basic Shares Outstanding | 30.1M | 29.8M | 29.5M | -- | 28.0M | 27.5M | 27.0M | 26.6M |
| Diluted Shares Outstanding | 30.1M | 29.8M | 29.5M | -- | 28.0M | 27.5M | 27.0M | 26.6M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $4.03M | $498K |
| **Cash & Short-Term Investments** | $4.03M | $498K |
| **Total Current Assets** | $5.20M | $1.10M |
| Intangible Assets | $922K | $822K |
| **Total Non-Current Assets** | $6.97M | $951K |
| **Total Assets** | $12.16M | $2.05M |
| **Total Current Liabilities** | $6.00M | $708K |
| Deferred Revenue (Non-Current) | $1.44M | $1.44M |
| **Total Non-Current Liabilities** | $1.47M | $1.52M |
| **Total Liabilities** | $7.48M | $2.23M |
| **Total Debt (incl. Leases)** | $80K | $121K |
| Common Stock | $2.9K | $2.7K |
| Retained Earnings | -$22.39M | -$19.20M |
| **Total Stockholders' Equity** | $4.69M | -$177K |
| Total Equity | $4.69M | -$177K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $9.43M | $9.95M | $11.01M | $4.03M | $514K | $498K |
| **Cash & Short-Term Investments** | $9.43M | $9.95M | $11.01M | $4.03M | $514K | $498K |
| **Total Current Assets** | $11.08M | $10.43M | $11.45M | $5.20M | $3.29M | $1.10M |
| Intangible Assets | $913K | $911K | $920K | $922K | $905K | $822K |
| **Total Non-Current Assets** | $5.27M | $6.53M | $7.19M | $6.97M | $1.00M | $951K |
| **Total Assets** | $16.35M | $16.96M | $18.64M | $12.16M | $4.30M | $2.05M |
| Short-Term Debt | $444K | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $3.48M | $8.76M | $5.13M | $6.00M | $2.31M | $708K |
| Long-Term Debt | $5.74M | $6.06M | $5.94M | -- | -- | -- |
| Deferred Revenue (Non-Current) | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M |
| **Total Non-Current Liabilities** | $7.18M | $7.51M | $7.40M | $1.47M | $1.48M | $1.52M |
| **Total Liabilities** | $10.66M | $16.27M | $12.53M | $7.48M | $3.79M | $2.23M |
| **Total Debt (incl. Leases)** | $6.23M | $6.12M | $6.01M | $80K | $91K | $121K |
| Common Stock | $3.1K | $3.0K | $3.0K | $2.9K | $2.8K | $2.7K |
| Retained Earnings | -$35.44M | -$29.21M | -$23.36M | -$22.39M | -$22.67M | -$19.20M |
| **Total Stockholders' Equity** | $5.69M | $687K | $6.12M | $4.69M | $504K | -$177K |
| Total Equity | $5.69M | $687K | $6.12M | $4.69M | $504K | -$177K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$3.19M | -$1.77M |
| Depreciation & Amortization | $53K | $47K |
| Stock-Based Compensation | $419K | $353K |
| **Operating Cash Flow** | -$2.56M | -$1.36M |
| **Investing Cash Flow** | -$153K | -$99K |
| Common Stock Issued | $6.92M | $1.15M |
| **Financing Cash Flow** | $6.92M | $1.15M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$6.23M | -$5.85M | -$971K | $279K | -$1.90M | -$1.24M | -$329K | -$666K |
| Stock-Based Compensation | $713K | $419K | $281K | $256K | $39K | $47K | $77K | -- |
| **Operating Cash Flow** | -$1.55M | -$923K | -$1.63M | -$1.18M | -$589K | -$500K | -$298K | -- |
| **Investing Cash Flow** | -$16K | -$5.8K | -$12K | -- | -- | -- | -- | -- |
| Common Stock Issued | -- | -- | -- | $3.77M | $0 | $2.15M | $998K | -- |
| **Financing Cash Flow** | $1.64M | $1 | $7.79M | $3.18M | $595K | $2.15M | $998K | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Equity (ROE) | -68.2% | -- |
| Return on Assets (ROA) | -26.3% | -86.3% |
| Current Ratio | 0.87x | 1.55x |
| Quick Ratio | 0.67x | 0.70x |
| Debt to Equity | 0.02x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -224.4% | -1229.6% | -62.7% | -68.2% | -- | -- | -- | -- |
| Return on Assets (ROA) | -78.1% | -49.8% | -20.6% | -26.3% | -- | -- | -- | -- |
| Current Ratio | 3.19x | 1.19x | 2.23x | 0.87x | 1.43x | -- | -- | -- |
| Quick Ratio | 2.71x | 1.14x | 2.15x | 0.67x | 0.22x | -- | -- | -- |
| Debt to Equity | 1.09x | 8.91x | 0.98x | 0.02x | 0.18x | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
